Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dyslipidemia
  Free Subscription

Articles published in
Atherosclerosis
    April 2024
  1. BASHIR B, Kwok S, Wierzbicki AS, Jones A, et al
    Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS).
    Atherosclerosis. 2024;391:117476.
    >> Share

    March 2024
  2. SCHLEGEL A
    Diagnostic challenge of an APOB variant of uncertain significance resolved by transheterozygosity with a pathological LDLR variant and clinical response to therapy.
    Atherosclerosis. 2024;390:117460.
    >> Share

    February 2024
  3. AGBAJE AO
    Increasing lipids with risk of worsening cardiac damage in 1595 adolescents: A 7-year longitudinal and mediation study.
    Atherosclerosis. 2024;389:117440.
    >> Share

  4. NOVO G, Arcari L, Stiermaier T, Alaimo C, et al
    Statin therapy and outcome in Takotsubo syndrome patients: Results from the multicenter international GEIST registry.
    Atherosclerosis. 2024;389:117421.
    >> Share

    January 2024
  5. RAGGI P, Takyar FM, Gadiyaram V, Zhang C, et al
    Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial.
    Atherosclerosis. 2024;388:117425.
    >> Share

    December 2023
  6. WODAJE T, Mahdi A, Venkateshvaran A, Habel H, et al
    Higher prevalence of coronary microvascular dysfunction in asymptomatic individuals with high levels of lipoprotein(a) with and without heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2023;389:117439.
    >> Share

  7. ANDRADE MM, Neto Goncalves T, Cruz D
    Familial hypercholesterolemia diagnostic challenge: Is Artificial Intelligence the key?
    Atherosclerosis. 2023 Dec 27:117435. doi: 10.1016/j.atherosclerosis.2023.117435.
    >> Share

  8. FISHBEIN I, Inamdar VV, Alferiev IS, Bratinov G, et al
    Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide.
    Atherosclerosis. 2023;390:117432.
    >> Share

    November 2023
  9. MOLOKHIA M, Wierzbicki AS, Williams H, Kirubakaran A, et al
    Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): A cross-sectional database study in Lambeth, South London.
    Atherosclerosis. 2023;388:117353.
    >> Share

  10. ZUBIRAN R, Vargas-Vazquez A, Olvera FDR, Cruz-Bautista I, et al
    Performance of the enhanced Sampson-NIH equation for VLDL-C and LDL-C in a population with familial combined hyperlipidemia.
    Atherosclerosis. 2023;386:117364.
    >> Share

  11. HOLVEN KB, Roeters van Lennep J
    Sex differences in lipids: A life course approach.
    Atherosclerosis. 2023;384:117270.
    >> Share

  12. GOLDBERG AC, Banach M, Catapano AL, Duell PB, et al
    Evaluation of the efficacy and safety of bempedoic acid in women and men: Pooled analyses from phase 3 trials.
    Atherosclerosis. 2023;384:117192.
    >> Share

  13. GAVINA C, Araujo F, Teixeira C, Ruivo JA, et al
    Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study.
    Atherosclerosis. 2023;384:117148.
    >> Share

    October 2023
  14. KATZMANN JL, Laufs U
    Liver transplantation for homozygous familial hypercholesterolemia: Cure for a genetic disease?
    Atherosclerosis. 2023 Oct 16:117337. doi: 10.1016/j.atherosclerosis.2023.117337.
    >> Share

  15. JUNNA N, Ruotsalainen S, Ripatti P, FinnGen, et al
    Novel Finnish-enriched variants causing severe hypercholesterolemia and their clinical impact on coronary artery disease.
    Atherosclerosis. 2023 Oct 12:117327. doi: 10.1016/j.atherosclerosis.2023.117327.
    >> Share

  16. PAGE MM, Hardikar W, Alex G, Bates S, et al
    Long-term outcomes of liver transplantation for homozygous familial hypercholesterolaemia in Australia and New Zealand.
    Atherosclerosis. 2023 Oct 10:117305. doi: 10.1016/j.atherosclerosis.2023.117305.
    >> Share

  17. RAJA V, Aguiar C, Alsayed N, Chibber YS, et al
    Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.
    Atherosclerosis. 2023;383:117312.
    >> Share

  18. SANTOS RD
    Improving pediatric familial hypercholesterolemia diagnosis by looking deeper into families.
    Atherosclerosis. 2023 Oct 1:117317. doi: 10.1016/j.atherosclerosis.2023.117317.
    >> Share

    September 2023
  19. ALBUQUERQUE J, Medeiros AM, Alves AC, Jannes CE, et al
    Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adults.
    Atherosclerosis. 2023;383:117314.
    >> Share

    August 2023
  20. CASULA M, Gazzotti M, Capra ME, Olmastroni E, et al
    Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
    Atherosclerosis. 2023 Aug 12:117231. doi: 10.1016/j.atherosclerosis.2023.117231.
    >> Share

  21. SHAPIRO MD, Taub PR, Louie MJ, Lei L, et al
    Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
    Atherosclerosis. 2023;378:117182.
    >> Share

  22. MURPHY JM, Jeong K, Tran DTK, Cioffi DL, et al
    Nuclear FAK in endothelium: An intrinsic inhibitor of NF-kappaB activation in atherosclerosis.
    Atherosclerosis. 2023;379:117189.
    >> Share

    July 2023
  23. SIMONEN P, Oorni K, Sinisalo J, Strandberg TE, et al
    High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?
    Atherosclerosis. 2023;376:53-62.
    >> Share

    June 2023
  24. JONES A, Peers K, Wierzbicki AS, Ramachandran R, et al
    Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS).
    Atherosclerosis. 2023;375:67-74.
    >> Share

  25. CASAS-DEZA D, Espina S, Martinez-Sapina A, Del Moral-Bergos R, et al
    Triglyceride-rich lipoproteins and insulin resistance in patients with chronic hepatitis C receiving direct-acting antivirals.
    Atherosclerosis. 2023;375:59-66.
    >> Share

  26. COSIN-SALES J, Campuzano Ruiz R, Diaz Diaz JL, Escobar Cervantes C, et al
    Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
    Atherosclerosis. 2023;375:38-44.
    >> Share

    May 2023
  27. DOI T, Langsted A, Nordestgaard BG
    Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality.
    Atherosclerosis. 2023 May 13:S0021-9150(23)00204.
    >> Share

  28. DOU Y, Chen B, Yu X, Ma D, et al
    Effectiveness of Internet-based health management in patients with dyslipidemia: A four-year longitudinal study.
    Atherosclerosis. 2023;376:34-42.
    >> Share

  29. SONMEZ A, Demirci I, Haymana C, Tasci I, et al
    Clinical characteristics of adult and paediatric patients with familial hypercholesterolemia: A real-life cross-sectional study from the Turkish National Database.
    Atherosclerosis. 2023;375:9-20.
    >> Share

  30. VAN EENIGE R, Ying Z, Tramper N, Wiebing V, et al
    Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.
    Atherosclerosis. 2023;372:19-31.
    >> Share

  31. RISIKESAN J, Heeboll S, Kumarathas I, Funck KL, et al
    Exercise increases myocardial free fatty acid oxidation in subjects with metabolic dysfunction-associated fatty liver disease.
    Atherosclerosis. 2023;372:10-18.
    >> Share

    April 2023
  32. RODRIGUEZ-BORJABAD C, Narveud I, Christensen JJ, Ibarretxe D, et al
    Association between Nordic and Mediterranean diets with lipoprotein phenotype assessed by (1)HNMR in children with familial hypercholesterolemia.
    Atherosclerosis. 2023;373:38-45.
    >> Share

  33. SCHREUDER MM, Hamkour S, Siegers KE, Holven KB, et al
    LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Atherosclerosis. 2023 Apr 13:S0021-9150(23)00139.
    >> Share

  34. HEDEGAARD BS, Bork CS, Kanstrup HL, Thomsen KK, et al
    Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study.
    Atherosclerosis. 2023;373:10-16.
    >> Share

    March 2023
  35. TADA H, Nomura A, Nohara A, Usui S, et al
    Attainment of the low-density lipoprotein cholesterol treatment target and prognosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2023 Mar 17:S0021-9150(23)00103.
    >> Share

  36. STANKOV S, Cuchel M
    Gene editing for dyslipidemias: New tools to "cut" lipids.
    Atherosclerosis. 2023;368:14-24.
    >> Share

    February 2023
  37. LI N, Zhang X, Zhang M, Wu L, et al
    Associations of genetically determined lipid traits and lipid-modifying agents with the risk of diabetic retinopathy: A Mendelian randomization study.
    Atherosclerosis. 2023;369:9-16.
    >> Share

    January 2023
  38. TSABAN G, Peles I, Barrett O, Abramowitz Y, et al
    Nonobstructive coronary atherosclerosis is associated with adverse prognosis among patients diagnosed with myocardial infarction without obstructive coronary arteries.
    Atherosclerosis. 2023;366:8-13.
    >> Share

  39. AGBAJE AO, Lloyd-Jones DM, Magnussen CG, Tuomainen TP, et al
    Cumulative dyslipidemia with arterial stiffness and carotid IMT progression in asymptomatic adolescents: A simulated intervention longitudinal study using temporal inverse allocation model.
    Atherosclerosis. 2023;364:39-48.
    >> Share

    December 2022
  40. FARIA R, Saramago P, Cox E, Weng S, et al
    How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis.
    Atherosclerosis. 2022 Dec 29:S0021-9150(22)01557.
    >> Share

  41. KAMSTRUP PR
    Lipoprotein(a) and familial hypercholesterolemia: Partners in crime in heritable hyperlipidemia.
    Atherosclerosis. 2022 Dec 24:S0021-9150(22)01570.
    >> Share

  42. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Cardiovascular disease onset in old people with severe hypercholesterolemia.
    Atherosclerosis. 2022;365:9-14.
    >> Share

  43. PINZON GRIMALDOS A, Pacella I, Bini S, Tucci G, et al
    ANGPTL3 deficiency associates with the expansion of regulatory T cells with reduced lipid content.
    Atherosclerosis. 2022;362:38-46.
    >> Share

    November 2022
  44. TROMP TR, Ibrahim S, Nurmohamed NS, Peter J, et al
    Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia.
    Atherosclerosis. 2022 Nov 29:S0021-9150(22)01530.
    >> Share

  45. NICHOLLS SJ
    Scratching the surface of atherosclerosis: Distinguishing phenotypes of plaque erosion.
    Atherosclerosis. 2022;360:42-43.
    >> Share

    October 2022
  46. CEFALU AB, D'Erasmo L, Iannuzzo G, Noto D, et al
    Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
    Atherosclerosis. 2022;359:13-19.
    >> Share

    August 2022
  47. MICHIKURA M, Hori M, Ogura M, Hosoda K, et al
    The impact of gene variants on the thickness and softness of the Achilles tendon in familial hypercholesterolemia.
    Atherosclerosis. 2022;358:41-46.
    >> Share

  48. SVENDSEN K, Olsen T, Vinknes KJ, Mundal LJ, et al
    Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study.
    Atherosclerosis. 2022;358:34-40.
    >> Share

  49. MIZUTA MH, Santos RD
    Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia.
    Atherosclerosis. 2022 Aug 22. pii: S0021-9150(22)01389.
    >> Share

    July 2022
  50. MCKAY AJ, Gunn LH, Ray KK
    Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort.
    Atherosclerosis. 2022 Jul 21. pii: S0021-9150(22)01352.
    >> Share

    June 2022
  51. JAHN B, Santamaria J, Dieplinger H, Binder CJ, et al
    Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions.
    Atherosclerosis. 2022;355:15-29.
    >> Share

  52. TAMURA K, Kumagai T, Kobayashi K
    Possible clinical usefulness of polygenic risk scores among patients with established atherosclerotic cardiovascular disease.
    Atherosclerosis. 2022;350:100-101.
    >> Share

  53. LIN H, Xuan L, Xiang J, Hou Y, et al
    Changes in adiposity modulate the APOA5 genetic effect on blood lipids: A longitudinal cohort study.
    Atherosclerosis. 2022;350:1-8.
    >> Share

    May 2022
  54. CHEMELLO K, Chan DC, Lambert G, Watts GF, et al
    Recent advances in demystifying the metabolism of lipoprotein(a).
    Atherosclerosis. 2022;349:82-91.
    >> Share

  55. PEDERIVA C, Capra ME, Biasucci G, Banderali G, et al
    Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group.
    Atherosclerosis. 2022;349:233-239.
    >> Share

  56. RIDER DA, Eisermann M, Loffler K, Aleku M, et al
    Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.
    Atherosclerosis. 2022;349:240-247.
    >> Share

    April 2022
  57. TENG H, Gao Y, Wu C, Zhang H, et al
    Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35-75 years: Results from China PEACE Million Persons Project.
    Atherosclerosis. 2022;350:58-64.
    >> Share

    March 2022
  58. NOTO D, Spina R, Giammanco A, Barbagallo CM, et al
    Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients.
    Atherosclerosis. 2022;347:63-67.
    >> Share

  59. MULDER JWCM, Kranenburg LW, Treling WJ, Hovingh GK, et al
    Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: A qualitative study.
    Atherosclerosis. 2022 Mar 12. pii: S0021-9150(22)00136.
    >> Share

    February 2022
  60. STOCK JK
    Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed.
    Atherosclerosis. 2022 Feb 20. pii: S0021-9150(22)00077.
    >> Share

    January 2022
  61. PECHLANER R, Friedrich N, Staudt A, Gande N, et al
    Association of adolescent lipoprotein subclass profile with carotid intima-media thickness and comparison to adults: Prospective population-based cohort studies.
    Atherosclerosis. 2022;341:34-42.
    >> Share

  62. PAQUETTE M, Baass A
    Polygenic risk scores for cardiovascular disease prediction in the clinical practice: Are we there?
    Atherosclerosis. 2022;340:46-47.
    >> Share

  63. CATAPANO AL, Ray KK, Tokgozoglu L
    Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future.
    Atherosclerosis. 2022;340:51-52.
    >> Share

    December 2021
  64. TRINDER M, Vikulova D, Pimstone S, Mancini GBJ, et al
    Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.
    Atherosclerosis. 2021;340:35-43.
    >> Share

  65. TADA H, Okada H, Nohara A, Takamura M, et al
    Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;340:28-34.
    >> Share

    November 2021
  66. CHAKRABORTY A, Pang J, Chan DC, Ellis KL, et al
    Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a).
    Atherosclerosis. 2021 Nov 12. pii: S0021-9150(21)01417.
    >> Share

  67. SANCHEZ-RAMOS A, Fernandez-Labandera C, Vallejo-Vaz A, Bonacho EC, et al
    Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study.
    Atherosclerosis. 2021;338:39-45.
    >> Share

  68. TROMP TR, Cupido AJ, Reeskamp LF, Stroes ESG, et al
    Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia.
    Atherosclerosis. 2021 Nov 2. pii: S0021-9150(21)01413.
    >> Share

    October 2021
  69. LEONARDI-BEE J, Boateng C, Faria R, Eliman K, et al
    Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2021;338:7-14.
    >> Share

  70. AHMED AI, Han Y, Al Rifai M, Alnabelsi T, et al
    Added prognostic value of plaque burden to computed tomography angiography and myocardial perfusion imaging.
    Atherosclerosis. 2021;334:9-16.
    >> Share

    September 2021
  71. STOCK JK
    Global Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Atherosclerosis. 2021 Sep 23. pii: S0021-9150(21)01361.
    >> Share

  72. PAQUETTE M, Bernard S, Baass A
    Hemoglobin concentration, hematocrit and red blood cell count predict major adverse cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:41-46.
    >> Share

  73. KLEVMOEN M, Bogsrud MP, Retterstol K, Svilaas T, et al
    Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:8-15.
    >> Share

  74. KOSUGI T, Eriguchi M, Yoshida H, Tasaki H, et al
    Association between chronic kidney disease and new-onset dyslipidemia: The Japan Specific Health Checkups (J-SHC) study.
    Atherosclerosis. 2021;332:24-32.
    >> Share

    August 2021
  75. MARCO-BENEDI V, Cenarro A, Laclaustra M, Larrea-Sebal A, et al
    Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation.
    Atherosclerosis. 2021 Aug 23. pii: S0021-9150(21)01270.
    >> Share

  76. DYRBUS K, Gasior M, Desperak P, Trzeciak P, et al
    Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry.
    Atherosclerosis. 2021;333:16-23.
    >> Share

  77. TOMBLING BJ, Zhang Y, Huang YH, Craik DJ, et al
    The emerging landscape of peptide-based inhibitors of PCSK9.
    Atherosclerosis. 2021;330:52-60.
    >> Share

    July 2021
  78. KATZMANN JL, Lehmann M, Tunnemann-Tarr A, An Haack I, et al
    Cutaneous manifestations in familial hypercholesterolaemia.
    Atherosclerosis. 2021 Jul 11. pii: S0021-9150(21)01236.
    >> Share

  79. KHALIL YA, Rabes JP, Boileau C, Varret M, et al
    APOE gene variants in primary dyslipidemia.
    Atherosclerosis. 2021;328:11-22.
    >> Share

  80. ALVES AC, Azevedo S, Benito-Vicente A, Graca R, et al
    LDLR variants functional characterization: Contribution to variant classification.
    Atherosclerosis. 2021;329:14-21.
    >> Share

    June 2021
  81. MALO AI, Girona J, Ibarretxe D, Rodriguez-Borjabad C, et al
    Serum glycoproteins A and B assessed by (1)H-NMR in familial hypercholesterolemia.
    Atherosclerosis. 2021;330:1-7.
    >> Share

  82. PAQUETTE M, Fantino M, Bernard S, Baass A, et al
    Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;329:9-13.
    >> Share

    May 2021
  83. REESKAMP LF, Nurmohamed NS, Bom MJ, Planken RN, et al
    Marked plaque regression in homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021;327:13-17.
    >> Share

  84. HEIDEMANN BE, Wolters FJ, Kavousi M, Gruppen EG, et al
    Adiposity and the development of dyslipidemia in APOE epsilon2 homozygous subjects: A longitudinal analysis in two population-based cohorts.
    Atherosclerosis. 2021;325:57-62.
    >> Share

  85. LEE JH, Lee HS, Cho AR, Lee YJ, et al
    Relationship between muscle mass index and LDL cholesterol target levels: Analysis of two studies of the Korean population.
    Atherosclerosis. 2021;325:1-7.
    >> Share

    April 2021
  86. BRANDTS J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, et al
    A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Atherosclerosis. 2021;325:46-56.
    >> Share

  87. INGOE L, Potter A, Musson S, Neely D, et al
    Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
    Atherosclerosis. 2021;325:38-45.
    >> Share

  88. SUADONI MT
    Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence.
    Atherosclerosis. 2021;323:57-58.
    >> Share

  89. ZAFEIROPOULOS S, Farmakis I, Kartas A, Arvanitaki A, et al
    Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial.
    Atherosclerosis. 2021;323:37-43.
    >> Share

  90. LIMA JG, Helena C Nobrega L, Moura Bandeira FT, Pires Sousa AG, et al
    A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
    Atherosclerosis. 2021;322:31-38.
    >> Share

  91. JO SH, Han SH, Kim SH, Eckel RH, et al
    Cardiovascular effects of omega-3 fatty acids: Hope or hype?
    Atherosclerosis. 2021;322:15-23.
    >> Share

    March 2021
  92. BUONUOMO PS, Mastrogiorgio G, Leone G, Rana I, et al
    Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021 Mar 28. pii: S0021-9150(21)00147.
    >> Share

  93. ELLINS EA, Watkins S, Rees DA, Datta DBN, et al
    Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2021 Mar 27. pii: S0021-9150(21)00144.
    >> Share

  94. BIESECKER LG
    Correspondence on: "Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features".
    Atherosclerosis. 2021 Mar 20. pii: S0021-9150(21)00125.
    >> Share

  95. BANACH M, Penson PE
    Lipid-lowering therapies: Better together.
    Atherosclerosis. 2021;320:86-88.
    >> Share

    February 2021
  96. LEREN TP, Bogsrud MP
    Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
    Atherosclerosis. 2021;322:61-66.
    >> Share

  97. REESKAMP LF, Balvers M, Peter J, van de Kerkhof L, et al
    Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
    Atherosclerosis. 2021;321:14-20.
    >> Share

    January 2021
  98. VUORIO A, Raal F, Kaste M, Kovanen PT, et al
    Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.
    Atherosclerosis. 2021;320:53-60.
    >> Share

  99. MARCO-BENEDI V, Laclaustra M, Bea AM, Suarez-Tembra M, et al
    Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Atherosclerosis. 2021;320:47-52.
    >> Share

  100. FUTEMA M, Ramaswami U, Tichy L, Bogsrud MP, et al
    Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2021;319:108-117.
    >> Share

  101. VALLEJO-VAZ AJ, Packard CJ, Ference BA, Santos RD, et al
    LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
    Atherosclerosis. 2021;320:1-9.
    >> Share

  102. KOROSOGLOU G, Chatzizisis YS, Raggi P
    Coronary computed tomography angiography in asymptomatic patients: Still a taboo or precision medicine?
    Atherosclerosis. 2021;317:47-49.
    >> Share

  103. STOCK JK
    Should we treat high LDL cholesterol in 'healthy' elderly individuals?
    Atherosclerosis. 2021;317:50-51.
    >> Share

    December 2020
  104. RUBINO J, MacDougall DE, Sterling LR, Hanselman JC, et al
    Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis. 2020 Dec 31. pii: S0021-9150(20)31597.
    >> Share

  105. SVENDSEN K, Krogh HW, Igland J, Tell GS, et al
    2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
    Atherosclerosis. 2020;319:28-34.
    >> Share

  106. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Atherosclerosis. 2020;318:32-37.
    >> Share

  107. SVENDSEN K, Langslet G, Krogh HW, Brinck J, et al
    Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.
    Atherosclerosis. 2020;316:48-52.
    >> Share

    November 2020
  108. PEREZ DE ISLA L, Alonso R, Gomez de Diego JJ, Muniz-Grijalvo O, et al
    Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study.
    Atherosclerosis. 2020 Nov 18. pii: S0021-9150(20)31521.
    >> Share

  109. REESKAMP LF, Tromp TR, Huijgen R, Stroes ESG, et al
    Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
    Atherosclerosis. 2020;315:68-75.
    >> Share

    October 2020
  110. IYEN B, Qureshi N, Weng S, Roderick P, et al
    Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
    Atherosclerosis. 2020 Oct 31. pii: S0021-9150(20)31491.
    >> Share

    September 2020
  111. IQBAL Z, Ho JH, Adam S, France M, et al
    Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
    Atherosclerosis. 2020;313:126-136.
    >> Share

  112. BERTOLINI S, Calandra S, Arca M, Averna M, et al
    Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
    Atherosclerosis. 2020;312:72-78.
    >> Share

    August 2020
  113. RODRIGUEZ-NOVOA S, Rodriguez-Jimenez C, Alonso C, Rodriguez-Laguna L, et al
    Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low density lipoprotein receptor (LDLR).
    Atherosclerosis. 2020;311:37-43.
    >> Share

  114. PEPPLINKHUIZEN S, Ibrahim S, Vink R, Groot B, et al
    Electronic health records to facilitate continuous detection of familial hypercholesterolemia.
    Atherosclerosis. 2020;310:83-87.
    >> Share

  115. ALJENEDIL S, Alothman L, Belanger AM, Brown L, et al
    Lomitapide for treatment of homozygous familial hypercholesterolemia: The Quebec experience.
    Atherosclerosis. 2020;310:54-63.
    >> Share

    July 2020
  116. RALLIDIS LS, Liberopoulos EN, Vlachopoulos C, Skoumas I, et al
    Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
    Atherosclerosis. 2020 Jul 30. pii: S0021-9150(20)30385.
    >> Share

  117. FUKUMOTO K, Takemoto Y, Yoshikawa J, Norioka N, et al
    Predictors of endothelial function improvement in patients with mild hypertriglyceridemia without evidence of coronary artery disease treated with purified eicosapentaenoic acid.
    Atherosclerosis. 2020;309:27-32.
    >> Share

  118. GULIZIA MM, Maggioni AP, Abrignani MG, Bilato C, et al
    Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study.
    Atherosclerosis. 2020;308:32-38.
    >> Share

  119. PASTA A, Cremonini AL, Formisano E, Fresa R, et al
    Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Atherosclerosis. 2020;308:6-14.
    >> Share

  120. STOCK J
    Familial hypercholesterolemia: An urgent public health priority.
    Atherosclerosis. 2020 Jul 18. pii: S0021-9150(20)30351.
    >> Share

  121. GALLO A, Charriere S, Vimont A, Chapman MJ, et al
    SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.
    Atherosclerosis. 2020;306:41-49.
    >> Share

    May 2020
  122. LAU P, Soubeyrand S, Hegele RA, Lagace TA, et al
    Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
    Atherosclerosis. 2020;304:39-43.
    >> Share

  123. STOCK JK
    Homozygous familial hypercholesterolaemia: New hope for getting patients to goal?
    Atherosclerosis. 2020 May 25. pii: S0021-9150(20)30230.
    >> Share

  124. ADEMI Z, Norman R, Pang J, Liew D, et al
    Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Atherosclerosis. 2020;304:1-8.
    >> Share

  125. TSIMIKAS S, Stroes ESG
    The dedicated "Lp(a) clinic": A concept whose time has arrived?
    Atherosclerosis. 2020;300:1-9.
    >> Share

    March 2020
  126. PANG J, Abraham A, Vargas-Garcia C, Bates TR, et al
    An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2020;298:52-57.
    >> Share

  127. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
    Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Atherosclerosis. 2020;296:40-47.
    >> Share

  128. CHO DH, Song IS, Choi J, Gwon JG, et al
    Risk of peripheral arterial disease in patients with periodontitis: A nationwide, population-based, matched cohort study.
    Atherosclerosis. 2020;297:96-101.
    >> Share

    February 2020
  129. LUIRINK IK, Hutten BA, Greber-Platzer S, Kolovou GD, et al
    Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
    Atherosclerosis. 2020;299:24-31.
    >> Share

  130. NORDESTGAARD BG, Langlois MR, Langsted A, Chapman MJ, et al
    Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
    Atherosclerosis. 2020;294:46-61.
    >> Share

    January 2020
  131. CHIU YW, Wu CS, Chen PC, Wei YC, et al
    Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
    Atherosclerosis. 2020;296:18-24.
    >> Share

  132. KOSKINEN JS, Kyto V, Juonala M, Viikari JSA, et al
    Childhood risk factors and carotid atherosclerotic plaque in adulthood: The Cardiovascular Risk in Young Finns Study.
    Atherosclerosis. 2020;293:18-25.
    >> Share

  133. SON DH, Lee HS, Lee YJ
    Association between serum carbohydrate antigen 19-9 levels and leukoaraiosis in middle-aged and older adults: A cross-sectional study.
    Atherosclerosis. 2020;292:188-192.
    >> Share

  134. MASUDA D, Miyata Y, Matsui S, Yamashita S, et al
    Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study.
    Atherosclerosis. 2020;292:163-170.
    >> Share

  135. MAEDA N, Funahashi T, Matsuzawa Y, Shimomura I, et al
    Adiponectin, a unique adipocyte-derived factor beyond hormones.
    Atherosclerosis. 2020;292:1-9.
    >> Share

    November 2019
  136. MULDER JWCM, Galema-Boers AMH, de Jong-Verweij LM, Hazelzet JA, et al
    The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health.
    Atherosclerosis. 2019;293:11-17.
    >> Share

  137. WALD DS, Bestwick JP
    Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies.
    Atherosclerosis. 2019;293:57-61.
    >> Share

  138. LAMIQUIZ-MONEO I, Restrepo-Cordoba MA, Mateo-Gallego R, Bea AM, et al
    Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.
    Atherosclerosis. 2019;292:143-151.
    >> Share

  139. RAMASWAMI U, Futema M, Bogsrud MP, Holven KB, et al
    Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2019;292:178-187.
    >> Share

    October 2019
  140. RAMOS R, Masana L, Comas-Cufi M, Garcia-Gil M, et al
    Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype.
    Atherosclerosis. 2019;292:42-51.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016